IGM 2324
Alternative Names: IGM-2324Latest Information Update: 05 Feb 2024
At a glance
- Originator IGM Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the ACR Convergence 2023 (ACR-2023)
- 14 Apr 2023 Preclinical trials in Cancer in USA (IV), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)